Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B7-H3 Antigen (CD276)
- Target
- CD276
- Molecular classification
- Immunoglobulin superfamily, B7 family, Type I transmembrane glycoprotein
01
Overview
B7-H3 (CD276) is an immune checkpoint protein belonging to the B7 family within the immunoglobulin superfamily. It acts as an immunoregulatory molecule with both costimulatory and coinhibitory functions, influencing T-cell mediated immune responses. While its precise physiological ligand remains unidentified, B7-H3 is frequently overexpressed in various solid tumors, making it a promising target for cancer therapy using monoclonal antibodies, CAR-T cell therapies, and antibody-drug conjugates.
- Other names
- CD276
02
Mechanism of action
Monoclonal antibodies, CAR-T cell therapies, antibody-drug conjugates targeting B7-H3 to inhibit tumor growth and promote immune response.
03
Biological functions
Immune checkpoint regulationCostimulationCoinhibitionModulating T cell responses
04
Disease associations
Cancer
05
Safety considerations
Potential for off-target effects due to B7-H3 expression in some normal tissuesImmune-related adverse events
06
Biomarkers
B7-H3 expression level in tumor tissueSoluble B7-H3 in serum
Beyond the preview
Go deeper on B7-H3 Antigen (CD276).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B7-H3 Antigen (CD276).